Please login to the form below

Not currently logged in
Email:
Password:

Inclisiran

This page shows the latest Inclisiran news and features for those working in and with pharma, biotech and healthcare.

Novartis sees demand returning to pre-COVID-19 levels in Q2 results

Novartis sees demand returning to pre-COVID-19 levels in Q2 results

mark. The company also said it had resubmitted its cholesterol-lowering med inclisiran in the US, after the Food and Drug Administration (FDA) issued a Complete Response Letter earlier this year ... In the EU, inclisiran is already approved under the

Latest news

More from news
Approximately 10 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Cortellis Drugs to Watch in 2020 report Cortellis Drugs to Watch in 2020 report

    8. Inclisiran from The Medicines Company (now a Novartis wholly owned subsidiary) is being reviewed for approval in hypercholesterolemia in the US and the EU. ... Inclisiran must leverage its strong efficacy and twice-a-year dosing to succeed.

  • 20 for 2020 – Five pharma leaders to watch in 2020 20 for 2020 – Five pharma leaders to watch in 2020

    Meanwhile, there’s considerable excitement about Novartis-partnered cholesterol-lowering therapy inclisiran, which is also up for an FDA decision this year and has been tipped to become a mega-blockbuster

  • Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe

    Alnylam has three more RNAi medicines in its late stage pipeline: Fitusiran in haemophilia, being co-developed with Sanofi; inclisiran for hypercholesterolemia being co-developed by the Medicines Company; and lumisiran

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Page & Page and Partners

For those who can imagine better, Page & Page and Partners (P&P) is home to meaningful encounters of a marketing, communication...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...